Date Name Title Filing Type Shares Traded Price Total Held
Dec 13, 2013
Director, Pres Regeneron Labs
Director, Pres Regeneron Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 203,204 -- 203,204
Aug 18, 2021
Director, President & CEO
Director, President & CEO Form 4 Open market or private sale of non-derivative or derivative security 200,000 $650.03 304,746
May 17, 2004
Director
Director Form 4 Bona fide gift 200,000 -- 62,360
May 17, 2004
Director
Director Form 4 Bona fide gift 200,000 -- 200,000
Nov 30, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 196,430 $28.01 1,066,135
Nov 30, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 196,430 -- --
Dec 13, 2017
Director, President & CSO
Director, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 195,438 $21.92 786,786
Dec 13, 2017
Director, President & CSO
Director, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 195,438 -- --
Dec 17, 2007
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 195,438 -- 195,438
Dec 15, 2016
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 195,079 $20.32 697,000

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.